



Supplementary Figure 1. Structural comparison of FitAB and VapBC. Left: The hetero-octameric structure of *N. gonorrhoeae* FitAB with the FitB toxin shown in sea green and the FitA antitoxin in yellow (PDB 2H1O¹⁷). The FitA antitoxins come together two-by-two to form two ribbon-helix-helix DNA binding domains (yellow, top and bottom). Right: The structure of hetero-octameric *S. flexneri* VapBC (this study) with the VapC toxin shown in blue and the VapB antitoxins in orange.



Supplementary Figure 2. Multiple sequence alignment of homologous VapB C-termini.

Sequences with 54-95% identity to *S. flexneri* VapB are aligned and shown with their UniProt ID. Only the VapC-interacting region is shown corresponding to residues 43-75 of *S. flexneri* VapB. Conserved residues are marked in blue and residues directly involved in VapC inhibition in the structure presented here are shown with red letters in the first line. The secondary structure of VapB is shown at the top.



Supplementary Figure 4. Affinity measurements of the VapBC-DNA interaction. (a)

Electrophoretic mobility shift assay (EMSA) with increasing concentrations of *S. flexneri* VapBC and constant amount of ^{32}P -labelled control DNA (lanes 1-6) or DNA I (lanes 7-14), see the Figure 5 legend for further details. DNA fragments were incubated with increasing concentrations of VapBC (0.2 - 2.5 ng/ μL) and DNA-protein complexes separated by 6% native PAGE. ! indicates unbound DNA and arrows shifted DNA-protein complexes. (b) Electrophoretic mobility shift assay (EMSA) with purified VapBC and ^{32}P -labelled DNA II (lanes 1-6) or DNA III (lanes 7-14). DNA fragments were incubated with increasing concentrations of VapBC (0.5 - 4 ng/ μL) and visualised as in (a).